Drug Profile
Research programme: vaccines containing toll-like receptor agonists - Aceragen/Merck
Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Aceragen; Merck & Co
- Class Alzheimer vaccines; Bacterial vaccines; Cancer vaccines; Oligonucleotides; Viral vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Bacterial infections; Cancer; Viral infections